Benzinga's Top #PreMarket Losers
Durata Therapeutics (NASDAQ: DRTX) dipped 11.19% to $15.00 in pre-market trading. Durata Therapeutics confirmed the FDA approval of Dalvance to treat skin infections.
JinkoSolar Holding Co (NYSE: JKS) shares fell 9.13% to $23.50 in pre-market trading after the company reported weaker-than-expected first-quarter earnings.
Staples (NASDAQ: SPLS) shares dropped 2.15% to $11.40 in pre-market trading after the company named Frank Bifulco as Executive Vice President, Marketing. Analysts at Goldman Sachs downgraded Staples from Neutral to Sell and lowered the target price from $11.50 to $11.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.